Table 4 Results of this analysis
Outcomes analyzed | OR with 95Â % CI | P value | I2 (%) |
|---|---|---|---|
Primary endpoints | 1.03 [0.65–1.64] | 0.90 | 0 |
Net clinical outcomes | 0.96 [0.69–1.34] | 0.81 | 0 |
Mortality | 0.87 [0.76–1.00] | 0.05 | 0 |
MI | 0.85 [0.70–1.04] | 0.12 | 0 |
TVR | 0.85 [0.58–1.24] | 0.39 | 0 |
TLR | 0.90 [0.57–1.41] | 0.63 | 0 |
Stroke | 0.94 [0.65–1.36] | 0.75 | 0 |
ST (definite or probable) | 0.56 [0.27–1.17] | 0.12 | 0 |
Definite ST | 0.63 [0.08–4.79] | 0.65 | 0 |
TIMI major bleeding | 0.91 [0.60–1.37] | 0.65 | 0 |
TIMI minor bleeding | 1.08 [0.62–1.91] | 0.78 | 0 |
BARC defined bleeding | 1.92 [1.58–2.34] | 0.00001 | 0 |
BARC type 2 | 1.98 [1.50–2.61] | 0.00001 | 0 |
BARC type 3 | 1.78 [1.34–2.37] | 0.0001 | 0 |
BARC type 5 | 1.40 [0.59–3.30] | 0.44 | 0 |